Which molecular markers to test in lung cancer patients being considered for targeted therapy.
Guidance on selecting molecular tests for lung cancer patients considered for targeted therapy.
A joint guideline from the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC) and the Association for Molecular Pathology (AMP). It defines which molecular markers should be tested in patients with lung cancer to guide selection of targeted (precision) therapies.
Lung adenocarcinoma can carry specific, treatable molecular alterations. Testing the right markers, such as EGFR mutations and ALK / ROS1 rearrangements, helps identify patients who may benefit from targeted therapy rather than standard chemotherapy alone.
For lung cases referred for molecular testing, our workflow references these recommendations to help ensure the clinically relevant markers are considered.
Tell us what you need, our team will help with sample requirements, turnaround, and reporting.